Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review DOI Creative Commons
Fabrizio Martora, Teresa Battista, Luca Potestio

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(12), P. 1896 - 1896

Published: Dec. 9, 2024

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous are available on a global scale based different mechanisms action, including mRNA technology, viral vectors, inactive viruses, subunit particles. Mass vaccination conducted worldwide highlighted potential side effects, ones with skin involvement. This review synthesizes data from 62 manuscripts, reporting total 142 cases autoimmune blistering diseases (AIBDs) following vaccination, comprising 59 pemphigus 83 bullous pemphigoid. Among pemphigoid cases, 78 were BP, additional 2 oral mucous membrane pemphigoid, 1 gestationis, anti-p200 dyshidrosiform BP. mean age affected individuals was 72 ± 12.7 years, an average symptom onset 11 10.8 days post-vaccination. Notably, 59% followed BNT162b2 (Pfizer-BioNTech), 51.8% new diagnoses, 45.8% occurred after second dose. purpose our is to analyze associated investigate pathogenetic underlying or flare-up these in association vaccination. Our results show that between AIBDs possible event.

Language: Английский

Bullous Pemphigoid: A practical approach to diagnosis and management in the modern era DOI
Camille M. Powers, Sach Thakker, Nicholas Gulati

et al.

Journal of the American Academy of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Factors Influencing the Clinical Course of Bullous Pemphigoid among Geriatric Patients: A Pilot Study DOI Creative Commons

Paula Mazan,

Aleksandra Lesiak, Igor Bednarski

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(10), P. 1701 - 1701

Published: Oct. 16, 2024

: Bullous pemphigoid (BP) is the most common autoimmune blistering disease affecting mainly elderly patients. Still, little known about pathogenesis of pruritus in BP or factors that affect clinical course disease. This study aimed to evaluate influencing among older

Language: Английский

Citations

0
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review DOI Creative Commons
Fabrizio Martora, Teresa Battista, Luca Potestio

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(12), P. 1896 - 1896

Published: Dec. 9, 2024

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous are available on a global scale based different mechanisms action, including mRNA technology, viral vectors, inactive viruses, subunit particles. Mass vaccination conducted worldwide highlighted potential side effects, ones with skin involvement. This review synthesizes data from 62 manuscripts, reporting total 142 cases autoimmune blistering diseases (AIBDs) following vaccination, comprising 59 pemphigus 83 bullous pemphigoid. Among pemphigoid cases, 78 were BP, additional 2 oral mucous membrane pemphigoid, 1 gestationis, anti-p200 dyshidrosiform BP. mean age affected individuals was 72 ± 12.7 years, an average symptom onset 11 10.8 days post-vaccination. Notably, 59% followed BNT162b2 (Pfizer-BioNTech), 51.8% new diagnoses, 45.8% occurred after second dose. purpose our is to analyze associated investigate pathogenetic underlying or flare-up these in association vaccination. Our results show that between AIBDs possible event.

Language: Английский

Citations

0